Systemic therapy for metastatic renal cell carcinoma (mRCC) has advanced considerably over the past decade. Studies of systemic therapies in the adjuvant, neoadjuvant, and now perioperative settings as solitary, dual, and triplet combinations are underway. The... ...

请注册登录后继续浏览